Business
Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021
Oral presentation of data from Phase 2a LIFT Trial of TERN-101, demonstrating differentiated safety and efficacy profiles 12 weeks of TERN-101 treatment
About this update from Terns Pharmaceuticals, Inc.
[{"type":"text","content":" Oral presentation of data from Phase 2a LIFT Trial of TERN-101, demonstrating differentiated safety and efficacy profiles 12 weeks of TERN-101 treatment significantly decreases cT1, a marker of liver inflammation and fibrosis, leading to study population shifts into cT1 categories associated with lower risk of clinical events Phase 1 data show single doses of TERN-501 are generally well-tolerated, produce significant LDL decreases and increases in SHBG, a key pharmacodynamic marker of THR-β engagement linked to NASH histologic efficacy FOSTER CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that multiple presentations of positive results from clinical trials of TERN-101 and TERN-501 will be delivered at The Liver Meeting® Digital Experience 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which will be held virtually from November 12-15, 2021. An oral presentation titled “Liver-distributed FXR Agonist TERN-101 Demonstrates Favorable Safety and Efficacy Profile in NASH Phase 2a LIFT Study” will be delivered by Rohit Loomba, M.D., MHSc, director of the UC San Diego NAFLD Research Center and director of Hepatology at UC San Diego School of Medicine. This presentation will highlight the safety and efficacy of TERN-101 after 12 weeks of treatment in patients with NASH. TERN-101 was overall safe and well-tolerated at all doses studied with no discontinuations due to adverse events, including pruritus. In the TERN-101 5 and 10 mg groups, no differences from placebo in percentage change in low density lipoprotein (LDL) cholesterol or high density lipoprotein (HDL) cholesterol from baseline to Week 12 were observed. TERN-101 demonstrated numerical reductions in alanine transaminase (ALT) and MRI proton density fat fraction (MRI-PDFF) in the 10 and 15 mg groups, and significant reductions in gamma-glutamyl transferase (GGT) in all dose groups. Corrected T1 (cT1), a marker of liver inflammation and fibrosis, declined significantly as early as Week 6 with persistent decreases through Week 12...